Literature DB >> 31685764

Evaluation of the Expression Time of Ganciclovir-Induced Adverse Events Using JADER and FAERS.

Go Ando1, Kazuaki Taguchi2, Yuki Enoki2, Yuta Yokoyama1, Junko Kizu1, Kazuaki Matsumoto1,2.   

Abstract

Investigation of the occurrence time of adverse drug reactions helps to prevent the development and aggravation of adverse reactions, but the expression time of ganciclovir-induced adverse events has not been elucidated. In this study, using databases of spontaneous adverse event reports, the Japanese Adverse Drug Event Report database (JADER) and the U.S. Food and Drug Administration (FDA)'s Adverse Event Reporting System (FAERS), the incidence of adverse reactions due to ganciclovir and their expression time were analyzed. As a result of calculation of the reporting odds ratio (ROR) and 95% confidence interval for individual main adverse reactions of ganciclovir (cytopenia, leukopenia, thrombocytopenia, liver damage, and acute renal failure), a signal was detected for all adverse reactions in both databases, except for liver damage in JADER. Furthermore, the Weibull distribution was performed for the analysis of onset time of each ganciclovir-induced adverse event. The results of Weibull parameter α and β values of each adverse event in both JADER and FAERS suggested that most adverse events occurred within 30 d and classified into the early failure type, except that thrombocytopenia and acute renal failure in JADER classified into the random failure type. Based on these findings, it concluded that the paying attention to signs of each ganciclovir-induced adverse event is required from the early phase after ganciclovir administration. However, in FAERS, development after a long-term course also accounted for 11%, suggesting that long-term periodic monitoring of adverse reactions would be also required.

Entities:  

Keywords:  data mining; database of spontaneous adverse event report; ganciclovir

Mesh:

Substances:

Year:  2019        PMID: 31685764     DOI: 10.1248/bpb.b19-00156

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

1.  Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database.

Authors:  Yuko Kanbayashi; Mayako Uchida; Misui Kashiwagi; Hitomi Akiba; Tadashi Shimizu
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

2.  Efficacy of small-dose ganciclovir on cytomegalovirus infections in children and its effects on liver function and miR-UL112-3p expression.

Authors:  Qingxiu Wang; Wenzeng Zhou; Bin Wang; Guoyun Qin; Feng'Ai Liu; Dexiang Liu; Tengteng Han
Journal:  Exp Ther Med       Date:  2021-06-29       Impact factor: 2.447

3.  Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database.

Authors:  Keiko Ogawa; Yoshihiro Kozuka; Hitomi Uno; Kosuke Utsumi; Osamu Noyori; Rumiko Hosoki
Journal:  Clin Drug Investig       Date:  2021-06-10       Impact factor: 2.859

4.  Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER.

Authors:  Toru Imai; Katsuyuki Hazama; Yasuhiro Kosuge; Shinichiro Suzuki; Susumu Ootsuka
Journal:  Sci Rep       Date:  2022-02-16       Impact factor: 4.379

5.  Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database.

Authors:  Yuko Kanbayashi; Mayako Uchida; Misui Kashiwagi; Hitomi Akiba; Tadashi Shimizu
Journal:  Sci Rep       Date:  2022-09-16       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.